PH12021550033A1 - Tumor reduction formulations and methods of use thereof - Google Patents
Tumor reduction formulations and methods of use thereofInfo
- Publication number
- PH12021550033A1 PH12021550033A1 PH12021550033A PH12021550033A PH12021550033A1 PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1 PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- tumor reduction
- formulations
- reduction formulations
- relates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000003229 sclerosing agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695613P | 2018-07-09 | 2018-07-09 | |
| PCT/US2019/040264 WO2020023191A1 (en) | 2018-07-09 | 2019-07-02 | Tumor reduction formulations and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550033A1 true PH12021550033A1 (en) | 2021-09-20 |
Family
ID=75267393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550033A PH12021550033A1 (en) | 2018-07-09 | 2021-01-06 | Tumor reduction formulations and methods of use thereof |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3820482A4 (https=) |
| JP (1) | JP2021530482A (https=) |
| KR (1) | KR20220098082A (https=) |
| CN (1) | CN112584841A (https=) |
| AU (1) | AU2019309757A1 (https=) |
| BR (1) | BR112021000279A8 (https=) |
| CA (1) | CA3105717A1 (https=) |
| EA (1) | EA202190201A1 (https=) |
| IL (1) | IL280000A (https=) |
| PH (1) | PH12021550033A1 (https=) |
| WO (1) | WO2020023191A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220152051A1 (en) * | 2019-03-15 | 2022-05-19 | Dalian University | Application of glycocholic acid in preparation of antitumor drugs |
| WO2020232227A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| US20210169903A1 (en) * | 2019-12-09 | 2021-06-10 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050202094A1 (en) * | 2004-01-29 | 2005-09-15 | Werling Jane O. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| WO2006099685A1 (en) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Method for the prophylaxis or treatment of carcinomas |
| CN101023940A (zh) * | 2006-02-20 | 2007-08-29 | 郝守祝 | 一种紫杉烷类化合物的药用组合物、制备方法及用途 |
| WO2016007741A1 (en) * | 2014-07-11 | 2016-01-14 | The Regents Of The University Of California | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies |
| US9687528B2 (en) * | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
| EP3429583A1 (en) * | 2016-03-15 | 2019-01-23 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
-
2019
- 2019-07-02 EA EA202190201A patent/EA202190201A1/ru unknown
- 2019-07-02 BR BR112021000279A patent/BR112021000279A8/pt not_active Application Discontinuation
- 2019-07-02 KR KR1020217003523A patent/KR20220098082A/ko not_active Withdrawn
- 2019-07-02 CA CA3105717A patent/CA3105717A1/en active Pending
- 2019-07-02 CN CN201980054337.1A patent/CN112584841A/zh active Pending
- 2019-07-02 AU AU2019309757A patent/AU2019309757A1/en not_active Abandoned
- 2019-07-02 EP EP19841949.1A patent/EP3820482A4/en not_active Withdrawn
- 2019-07-02 JP JP2021500520A patent/JP2021530482A/ja not_active Withdrawn
- 2019-07-02 WO PCT/US2019/040264 patent/WO2020023191A1/en not_active Ceased
-
2021
- 2021-01-06 PH PH12021550033A patent/PH12021550033A1/en unknown
- 2021-01-07 IL IL280000A patent/IL280000A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3105717A1 (en) | 2020-01-30 |
| IL280000A (en) | 2021-03-01 |
| AU2019309757A1 (en) | 2021-03-04 |
| EA202190201A1 (ru) | 2021-04-09 |
| BR112021000279A2 (pt) | 2021-04-06 |
| EP3820482A4 (en) | 2022-03-23 |
| WO2020023191A1 (en) | 2020-01-30 |
| KR20220098082A (ko) | 2022-07-11 |
| JP2021530482A (ja) | 2021-11-11 |
| CN112584841A (zh) | 2021-03-30 |
| BR112021000279A8 (pt) | 2021-04-20 |
| CN112584841A8 (zh) | 2021-06-18 |
| EP3820482A1 (en) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| PH12021550033A1 (en) | Tumor reduction formulations and methods of use thereof | |
| IL278829A (en) | The compositions containing bis-(fluoroalkyl)-1,4 benzodiazepines and immunotherapeutic substances and methods of using them | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| EP4272834A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MX383164B (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
| MX2019010984A (es) | Composiciones de sintecina y metodos de uso. | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| MX2017011521A (es) | Composiciones topicas que comprenden un corticosteroide. | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| ZA202001756B (en) | Oral care compositions | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| IL272834A (en) | Compositions of amantadine, their preparation, and methods of use | |
| ZA202000354B (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| MX2021000314A (es) | Formulaciones reductoras de tumores y metodos de uso de las mismas. | |
| GB201915829D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof |